TITLE

Femara

PUB. DATE
May 2008
SOURCE
Pharmaceutical Representative;May2008, Vol. 38 Issue 5, p13
SOURCE TYPE
Periodical
DOC. TYPE
Product Review
ABSTRACT
The article evaluates Dimebon from Medivation.
ACCESSION #
31900665

 

Related Articles

  • Corrections and Clarifications.  // BioWorld Today;6/13/2008, Vol. 19 Issue 115, p2 

    A correction to a news item which appeared on June 10, 2008 regarding the two studies by Medivation Inc. is presented.

  • Medivation reduces workforce by 20%.  // PharmaWatch: Biotechnology;May2010, Vol. 9 Issue 5, p24 

    The article reports on the reduction of workforce of approximately 20% by Medivation Inc. to focus its resources on prioritized dimebon trials and the continuation on the development of MDV31000.

  • Throwing out medical waste. Pope, Gregory T.; Chien, Philip // Popular Mechanics;Aug95, Vol. 172 Issue 8, p28 

    Reports on Medivators Inc.'s development of DSI System 2000, an on-site disposal unit that allows dangerous waste to be recycled or tossed out safely. System's destruction of infectious agents by baking waste in a high-temperature crucible; Environmental Protection Agency's (EPA) regulations on...

  • McKesson HBOC to buy MediVation. Tieman, Jeff // Modern Healthcare;07/10/2000, Vol. 30 Issue 28, p20 

    Reports on the acquisition of MediVation by McKesson HBOC. Information on MediVation; Statement from Michael Cataldo, MediVation's president and chief executive officer; Discussion on MediVation's services.

  • Medivation to initiate confirmatory Phase III Alzheimer's trial.  // PharmaWatch: CNS;Mar2008, Vol. 7 Issue 3, p7 

    The article reports on the plan of Medivation to set a confirmatory Phase III trial of Dimebon for the treatment of mild to moderate Alzheimer's disease in the second quarter of 2008. The trial will enroll about 525 patients with the disease at sites in the U.S., Europe and South America where...

  • TRADE NEWS.  // British Dental Journal;3/25/2000, Vol. 188 Issue 6, p340 

    Presents news updates on dentistry as of March 25, 2000. Finishing Techniques Ltd.'s introduction of the ECO finishing machine; I-glasses patient entertainment system by Medivance; Pure soap developed by Sentinel Laboratories.

  • Dimebon Yields Positive Phase II Results for AD.  // Bioworld Week;6/18/2007, Vol. 15 Issue 25, p3 

    The article reports on the positive Phase II results of the lead compound, Dimebon from Medivation Inc. of San Francisco, California. The company shows that the compound preserves function and prevents progressive deterioration in Alzheimer's disease patients after one year of therapy. The...

  • Mitochondria, Innate Immunity Both Play Roles in Huntington's. Breindl, Anette // BioWorld Today;7/16/2008, Vol. 19 Issue 137, p1 

    The article reports on the claim of Medivation Inc. that its mitochondria-targeting drug candidate, Dimebon, was shown to be safe and well tolerated and improved cognitive function compared to placebo in a study. In addition, a paper showed evidence that targeting mitochondria can be a promising...

  • Earnings Roundup.  // BioWorld Today;3/ 4/2013, Vol. 24 Issue 41, p2 

    The article offers news briefs related to the corporate profits of biopharmaceutical companies in the U.S. for the fourth quarter of 2012. Medivation Inc. posted a corporate profit of 57.4 million dollars. Salix Pharmaceuticals Ltd. reported a generally accepted accounting principles (GAAP) net...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics